# Rhythm Pharmaceuticals share price today (Rhythm Pharmaceuticals, Inc., RYTM)

> Rhythm Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. RYTM · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/rytm

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $105.02 (+4.7% in a year)
- Revenue (Jun 2026): $71.3 M (+46.9% on a year ago)
- Profit (Jun 2026): −$50.4 M
- Operating margin: −68.1% (+25.3 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Rhythm Pharmaceuticals share price today? Rhythm Pharmaceuticals, Inc.'s share price was $105.02 at the close on 5 November 2026. It has been stalling near its high for 1 week. That is 8.3% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 8 weeks running. In the last 52 weeks it traded between $76 and $116, and at that close it sat 73% of the way up from that low. Over the last 9.1 years the share price moved +316% while the S&P 500 moved +188%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Rhythm Pharmaceuticals pay? Rhythm Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Rhythm Pharmaceuticals on? Rhythm Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Rhythm Pharmaceuticals profitable? Rhythm Pharmaceuticals, Inc. posted a net loss of $50.4 M in the Jun 2026 quarter. The full FY25 year was a loss of $202 M. That loss is 70.7% of the quarter's revenue. The same quarter a year earlier lost $48.0 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Rhythm Pharmaceuticals make, and is it growing? Rhythm Pharmaceuticals, Inc. reported $71.3 M of revenue in the Jun 2026 quarter, +46.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 178.5% a year on average. The last full year, FY25, came in at $190 M. The last four reported quarters add to $240 M. FY25 revenue was $190 M, +45.8% on the year before. Recent pace: the last four quarters grew +55.5% on average, against 178.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +53.5%, against +53.5% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Rhythm Pharmaceuticals keep? Rhythm Pharmaceuticals, Inc.'s operating margin was −68.1% in the Jun 2026 quarter, 25.3 percentage points higher than the same quarter a year ago. Across 5 years it has been between −5,391.9% and −101.2%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +25.3 percentage points on the year while gross margin changed −1.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Rhythm Pharmaceuticals' profit turning into cash? Rhythm Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $116 M of cash, against −$202 M of profit. After $953 K of spending on assets, free cash was −$117 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Rhythm Pharmaceuticals' cash go? Rhythm Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.3 M on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.3 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Rhythm Pharmaceuticals' P/E ratio, and how does it compare with its own history? Rhythm Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Rhythm Pharmaceuticals, Inc. at 38.4× its FY25 revenue of $190 M. The P/E comes back here once profit turns positive. ## Is the Rhythm Pharmaceuticals business getting better or worse? Rhythm Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Rhythm Pharmaceuticals earn on its capital? Rhythm Pharmaceuticals, Inc. earned a ROE of −75% in FY25. That is up from a low of −161% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads −4,107%, a number that says nothing useful about the business. It comes from a −106.4% net margin and 0.40× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −106.4% net margin × 0.40× asset turnover × 1.78× leverage (assets divided by equity) ≈ −75.8% on equity. The margin does its share; borrowing is a big part of it. ## Does Rhythm Pharmaceuticals have too much debt? Rhythm Pharmaceuticals, Inc. has total debt of $110 M against shareholder equity of $217 M as of Jun 2026, so its debt is 0.51× its equity. Year by year, that ratio went from 0.01 in FY21 to 0.42 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Rhythm Pharmaceuticals shareholding pattern? 19.6% of Rhythm Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 13.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Rhythm Pharmaceuticals from balance-sheet trouble? For Rhythm Pharmaceuticals, Inc., the Z-score is 12.10. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 12.10 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Rhythm Pharmaceuticals rank in its industry? There is no score against its industry: Rhythm Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Rhythm Pharmaceuticals compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Rhythm Pharmaceuticals in size? Rhythm Pharmaceuticals is the 36th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: ABIVAX Société Anonyme, Caris Life Sciences, Inc. and Praxis Precision Medicines, Inc. Just below it: Axsome Therapeutics, Inc., Ionis Pharmaceuticals, Inc. and Mirum Pharmaceuticals, Inc. ### Biotechnology companies close in size

1. [ABIVAX Société Anonyme](https://www.sectoralpha.in/us/stocks/abvx) $7.6 billion
2. [Caris Life Sciences, Inc.](https://www.sectoralpha.in/us/stocks/cai) $7.5 billion
3. [Praxis Precision Medicines, Inc.](https://www.sectoralpha.in/us/stocks/prax) $7.3 billion
4. Rhythm Pharmaceuticals, Inc. $7.3 billion
5. [Axsome Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/axsm) $6.8 billion
6. [Ionis Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/ions) $6.4 billion
7. [Mirum Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mirm) $6.1 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [XP Inc.](https://www.sectoralpha.in/us/stocks/xp) $7.7 billion · Capital Markets
2. [SPX Technologies, Inc.](https://www.sectoralpha.in/us/stocks/spxc) $7.7 billion · Building Products & Equipment
3. Rhythm Pharmaceuticals, Inc. $7.7 billion
4. [The Macerich Company](https://www.sectoralpha.in/us/stocks/mac) $7.7 billion · REIT - Retail
5. [Vipshop Holdings Limited](https://www.sectoralpha.in/us/stocks/vips) $7.6 billion · Internet Retail

## What else do people ask about Rhythm Pharmaceuticals? ### What were Rhythm Pharmaceuticals's latest quarterly results? Rhythm Pharmaceuticals, Inc. reported revenue of $71.3 M and a net loss of $50.4 M for the Jun 2026 quarter. Earnings per share were −$0.73. The operating margin was −68.1%, 25.3 percentage points higher than a year earlier (as of 5 November 2026). ### What is Rhythm Pharmaceuticals's market cap? Rhythm Pharmaceuticals, Inc.'s market capitalisation is $7.3 B at a stock price of $105.02. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Rhythm Pharmaceuticals performing? Rhythm Pharmaceuticals, Inc.'s share price has been stalling near its high for 1 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 8 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Rhythm Pharmaceuticals's stock price go up? This page does not forecast Rhythm Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $105.02, and it has been stalling near its high for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Rhythm Pharmaceuticals have too much debt? Rhythm Pharmaceuticals, Inc. has a moderate amount of debt: its debt is 0.53× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### Where is Rhythm Pharmaceuticals in its business cycle? Rhythm Pharmaceuticals, Inc.'s FY25 operating margin was −101.2%, against a 5-year range of −5,391.9% to −101.2%: the middle of its own range, neither a peak nor a low. The latest quarter was −68.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Rhythm Pharmaceuticals story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Rhythm Pharmaceuticals a stock worth studying right now? What the numbers show: Rhythm Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.